S&P Futures
5,887.50 -5.00 (-0.08%) Dow Futures
43,041.00 -128.00 (-0.30%) Nasdaq Futures
20,517.00 -25.00 (-0.12%) Russell 2000 Futures
2,244.30 -1.90 (-0.08%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.40 -6.40 (-0.23%)
AB Science S.A. (AB.PA)
| Previous Close | 0.9350 |
| Open | 0.9400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.9400 - 0.9900 |
| 52 Week Range | 0.8800 - 4.4650 |
| Volume | |
| Avg. Volume | 31,119 |
| Market Cap | 64.729M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | Oct 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following a vote adopted during the Committee for Med
- GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by EMA and Health Canada of the marketing authorisation application for masitinib in amyotrophic lateral sclerosis (ALS)Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conferencePositive results from the phase 2 study of masitinib in Covid-19Strengthening the
